Bio-Path (NASDAQ:BPTH) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note released on Tuesday morning. The firm issued a sell rating on the stock.

Separately, Roth Mkm boosted their price objective on shares of Bio-Path from $12.00 to $40.00 and gave the company a buy rating in a report on Wednesday, March 27th.

Bio-Path Stock Performance

NASDAQ:BPTH opened at $3.02 on Tuesday. The company has a 50-day moving average of $5.71 and a 200-day moving average of $8.60. The company has a market capitalization of $2.05 million, a price-to-earnings ratio of -0.07 and a beta of 0.36. Bio-Path has a 52 week low of $2.70 and a 52 week high of $44.80.

Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings results on Friday, March 8th. The company reported ($5.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($5.40). During the same quarter in the prior year, the company earned ($10.60) EPS. Sell-side analysts forecast that Bio-Path will post -18.71 EPS for the current year.

Institutional Trading of Bio-Path

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Bio-Path by 77.5% in the fourth quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock valued at $125,000 after purchasing an additional 117,914 shares during the last quarter. Walleye Capital LLC acquired a new position in shares of Bio-Path in the third quarter valued at $77,000. Citadel Advisors LLC acquired a new position in shares of Bio-Path in the third quarter valued at $35,000. Renaissance Technologies LLC acquired a new position in shares of Bio-Path in the second quarter valued at $70,000. Finally, Virtu Financial LLC acquired a new position in shares of Bio-Path in the first quarter valued at $38,000. 5.74% of the stock is owned by institutional investors.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.